Topical Tacrolimus for the Treatment of Psoriasis on the Face, Genitalia, Intertriginous Areas and Corporal Plaques
April 2006 | Volume 5 | Issue 4 | Original Article | 334 | Copyright © April 2006
G. Martín Ezquerra MD, M. Sánchez Regaña MD, E. Herrera Acosta MD, P. Umbert Millet MD
Tacrolimus is an immunosuppressive drug that has proved effective in the treatment of psoriasis when administered systemically.
Topically, it seems only useful in thin psoriasis plaques located on the face, genitalia, and intertriginous areas. We
present an open-label clinical trial to test the efficacy of 0.1 % tacrolimus ointment in patients with psoriasis on the face,
intertriginous areas, both, and in corporal plaques. Efficacy was assessed with the evaluation of erythema, desquamation,
infiltration, reduction of the PASI, and reduction of itching. A total of 15 patients were enrolled in the study. In all the
localizations evaluated, each of the signs (erythema, desquamation, and infiltration) showed a statistically significant
improvement when compared to the baseline (p<.001). Itching also improved rapidly. PASI was also reduced from a mean
of 12 at baseline to 2.2 at the end of the study. Of the 15 patients, only 2 experienced an adverse effect (13%), which was
described as a warm sensation in facial lesions which was transient and self-limited. In conclusion, tacrolimus ointment may
be an alternative to classical options for the treatment of psoriasis, not only for intertriginous, genital, and facial areas, but
also for corporal plaques without occlusion, with good tolerance.